Bryant, Kirsten L.

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

Bryant, K. L., Stalnecker, C. A., Zeitouni, D., Klomp, J. E., Peng, S., Tikunov, A. P., Gunda, V., Pierobon, M., Waters, A. M., George, S. D., et al. (2019) · Nature Medicine

Autophagy in Disease and TherapyPancreatic and Hepatic Oncology Research

Cited by 692

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingPancreatic and Hepatic Oncology Research

Cited by 231

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer

Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., et al. (2023) · Cancer Research

Pancreatic and Hepatic Oncology ResearchAdvanced Breast Cancer Therapies

Cited by 168

Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer

Klomp, J. E., Diehl, J. N., Klomp, J. A., Edwards, A. C., Yang, R., Morales, A. J., Taylor, K. E., Drizyte-Miller, K., Bryant, K. L., Schaefer, A., et al. (2024) · Science

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 83

Abstract 1936: KEAP1-NRF2 mediated resistance against KRASG12D inhibitor in pancreatic ductal adenocarcinoma

Chang, W.-H., Stamey, A. G., Waters, A. M., Bryant, K. L., Cox, A. D., & Der, C. J. (2024) · Cancer Research

Pancreatic and Hepatic Oncology ResearchGenomics, phytochemicals, and oxidative stress

Cited by 1